1-5 of 5
Jonathan R. Fromm
Close
Sort by
Journal Articles

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

Clinical Trials & Observations
Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, Ted A. Gooley, Heather Rasmussen, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward N. Libby, III, Alexander L. Greninger, Jonathan R. Fromm, Ajay K. Gopal
Journal: Blood Advances
Blood Adv (2023) 7 (5): 687–696.
https://doi.org/10.1182/bloodadvances.2022008628
Published: 2023
Includes: Supplemental data
Journal Articles

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia

Clinical Trials & Observations
Jorge J. Castillo, Edward N. Libby, Stephen M. Ansell, M. Lia Palomba, Kirsten Meid, Catherine A. Flynn, Carly Leventoff, Christopher B. Hergott, Tomasz Sewastianik, Elizabeth A. Morgan, Ruben Carrasco, Jonathan R. Fromm, Guang Yang, Zachary Hunter, Steven P. Treon
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5089–5092.
https://doi.org/10.1182/bloodadvances.2020003087
Published: 2020
Journal Articles

Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia

Clinical Trials & Observations
Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Jonathan R. Fromm, Mary-Elizabeth M. Percival, Cameron J. Turtle, Paul T. Nghiem, Phillip A. Stevenson, Elihu H. Estey
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3239–3245.
https://doi.org/10.1182/bloodadvances.2020002403
Published: 2020
Includes: Supplemental data
Journal Articles

Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion

Kirsty Wienand, Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, David Wu, Jaegil Kim, Atanas Kamburov, Timothy R. Wood, Fathima Zumla Cader, Matthew D. Ducar, Aaron R. Thorner, Anwesha Nag, Alexander T. Heubeck, Michael J. Buonopane, Robert A. Redd, Kamil Bojarczuk, Lee N. Lawton, Philippe Armand, Scott J. Rodig, Jonathan R. Fromm, Gad Getz, Margaret A. Shipp
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4065–4080.
https://doi.org/10.1182/bloodadvances.2019001012
Published: 2019
Includes: Supplemental data
Journal Articles

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Vinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, Asen Bagashev, Derek A. Oldridge, Jaclyn Rosenthal, John Van Arnam, Jos J. Melenhorst, Diwakar Mohan, Amanda M. DiNofia, Minjie Luo, Sindhu Cherian, Jonathan R. Fromm, Gerald Wertheim, Andrei Thomas-Tikhonenko, Michele Paessler, Carl H. June, Eline T. Luning Prak, Vijay G. Bhoj, Stephan A. Grupp, Shannon L. Maude, Susan R. Rheingold
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3539–3549.
https://doi.org/10.1182/bloodadvances.2019000692
Published: 2019
Includes: Supplemental data